Surface Oncology, Inc.

SURFCIK 0001718108 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed May 1, 2023. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0008

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Surface Oncology, Inc.

Name	Roles	Filings
Shanafelt Armen	Director10% Owner	1
Stelzer Laurie	Director	1

Showing 16-17 of 17

Per pagePrevPage 4 of 4

All filings

42 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Sep 8, 2023	Adams Chandra Deputy GC	DDisposition	23,884	-	-
Sep 8, 2023	Sigal Charles Elliott Director	DDisposition	45,453	-	-
Sep 8, 2023	Fees Jessica Chief Financial Officer	DDisposition	101,915	-	-
Sep 8, 2023	Palombella Vito J. Chief Scientific Officer	DDisposition	87,212	-	-
Aug 11, 2023	Ross Robert W. Chief Executive Officer	SSale	16,713	$0.94	$15,710

Showing 6-10 of 42

Per pagePrevPage 2 of 9Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value